SciSparc Ltd. - Ordinary Shares (NQ: SPRC )

0.2380 -0.0091 (-3.68%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about SciSparc Ltd. - Ordinary Shares

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
SciSparc Closer To Phase II-B Trial Of Its Dronabinol Based Drug For The Treatment Of Tourette Syndrome
SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, has started the process of... 
Via Benzinga
SciSparc Announces Buyback Equal To 12% Of Float
SciSparc Ltd. (NASDAQ: SPRC) recently announced that its board of directors authorized the company to take actions to implement a $1 million buyback program for the Company’s ordinary shares, no par... 
Via Benzinga
Traders News Source Interviews Oz Adler Chief Executive Officer at SciSparc Ltd.
NEW YORK, NY / ACCESSWIRE / July 7, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid cap publicly traded companies recently issued a... 
From Traders News Source
Via AccessWire
SciSparc Completes Development Of Its Proprietary Drug Candidate SCI-110 To Treat Tourette Syndrome
SciSparc Ltd. (NASDAQ: SPRC) announced that it has successfully completed the development of its top-tier drug candidate SCI-110 to be used in its upcoming multinational, multicenter, Phase IIb study... 
Via Benzinga
SciSparc Awaiting Approval For Phase IIb Study Of Its Dronabinol Based Drug For Treatment Of Tourette Syndrome
SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, has successfully completed... 
Via Benzinga
SciSparc Successfully Completed The Development Of Its Proprietary Drug Candidate SCI-110 For Its Upcoming Phase IIb Study In Tourette Syndrome
TEL AVIV, Israel, June 29, 2022 /PRNewswire/ -- SciSparc Ltd. 
Via Benzinga
SciSparc Announces Ethics Committee Approval To Conduct Its Clinical Trial In Autism Spectrum Disorder
The Soroka University Ethics Committee Approval Received to Conduct a Clinical trial with SciSparc’s Proprietary SCI-210 Treatment 
Via Benzinga
SciSparc Reinforces Its New JV For Targeting Discovery With A Global Expert In The Field Of Mitochondrial Transport Proteins
JV Targets Potential Drugs for Cancers and Infectious Diseases 
Via Benzinga
R&D Efforts for Central Nervous System (CNS) Therapeutics Have Resulted in Hopeful Novel Drug-Delivery Solutions
Palm Beach, FL – June 29 2022 – FinancialNewsMedia.com News Commentary – In the central nervous system (CNS) therapeutics market, large and small pharmaceutical companies are highly investing in the... 
Via FinancialNewsMedia
SciSparc And Polyrizon Report Joining Forces To Develop A Non-Opioid Pain Relief Nasal Spray
The opioid crisis has raised public awareness about the dire state of pain-management options for the estimated 50 million Americans with chronic pain. 
Via Benzinga
SciSparc Receives Ethics Committee Approval To Conduct Clinical Trial In ASD With Proprietary SCI-210 Treatment
SciSparc Ltd. 
Via Benzinga
Initial Positive Results For Cocaine Addiction Treatment Announced
Photo by Annie Spratt on 
Via Benzinga
SciSparc Ltd. Announces Initial Positive Results For The Cocaine Addiction Treatment Of Clearmind Medicine Inc.
SciSparc and Clearmind recently announced the filing of a patent application related to treating cocaine addiction 
Via Benzinga
SciSparc To Collaborate With Polyrizon For Brain Targeting Using Intranasal Hydrogel Systems
SciSparc will use its SCI-160 technology platform for treating pain in combination with Polyrizons' Trap and TargetTM technology 
Via Benzinga
93 Biggest Movers From Yesterday
Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares surged 126% to close at $14.96 on Monday after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in... 
Via Benzinga
SciSparc Announces $10M Private Offering
SciSparc Ltd. 
Via Benzinga
70 Stocks Moving In Monday's Mid-Day Session
Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares jumped 110% to $13.93 after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in relapsed pediatric... 
Via Benzinga
Central Nervous System (CNS) Therapeutics Global Market Expected to Reach $154 Billion By 2027
Palm Beach, FL – June 9, 2022 – FinancialNewsMedia.com News Commentary – The central nervous system (CNS) consists of the brain and spinal cord and brain and nervous system problems are more common and... 
Via FinancialNewsMedia
EXCLUSIVE: SciSparc' Board To Review Potential Strategic Transactions
SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focused on the endocannabinoid system, plans to review potential strategic transactions. 
Via Benzinga
Psyched: Christie's Launches NFT Collection Supporting Psychedelic Science, Origin's Listing On CSE Gives Retail Investors Access To Private Companies
The world of psychedelics is getting a crossover with another category in the millennial catalog of trendy investments: NFTs. 
Via Benzinga
Rising Cases Of Mental Health Disorders of Stress, Anxiety & Addiction Fueling Need for Central Nervous System Therapeutics
Palm Beach, FL – June 7, 2022 – FinancialNewsMedia.com News Commentary – The global Central Nervous System (CNS) treatments and its market revenues had been steadily growing pre-pandemic and are still... 
Via FinancialNewsMedia
Exposures COVID-19
SciSparc & Clearmind Medicine Team Up On Patent For Psychedelic Combination To Treat Cocaine Addiction
SciSparc Ltd. (NASDAQ: SPRC) collaboration with Clearmind Medicine Inc. (OTCPK:CMNDF) (CSE:CMND) (FSE:CWY0) resulted in the filing of a provisional patent application related to treating cocaine... 
Via Benzinga
SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields Another Patent Application for their Proprietary Psychedelic Combination to Treat Cocaine Addiction
No dedicated treatment currently available for cocaine addiction 
Via Benzinga
Aegis Capital Corp. Acted as Exclusive Placement Agent on a $10 Million Private Placement Priced At-the-Market for SciSparc Ltd. (NASDAQ:SPRC).
NEW YORK, NY / ACCESSWIRE / June 2, 2022 / Aegis Capital Corp. acted as Exclusive Placement Agent on a $10 Million Private Placement Priced At-the-Market for SciSparc Ltd. (NASDAQ:SPRC). 
From Aegis Capital Corp.
Via AccessWire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Good morning, investors! Busy traders are already at work this morning as we go over the biggest pre-market stock movers for Wednesday. 
Via InvestorPlace
70 Biggest Movers From Friday
Gainers Avadel Pharmaceuticals plc (NASDAQ: AVDL) shares climbed 133.6% to close at $2.50 on Friday. Avadel Pharmaceuticals shares dipped 68% on Thursday after announcing new FDA request for... 
Via Benzinga
SciSparc Gets Ethics Committee Approval In Germany And Israel Sites To Conduct A Phase IIb Trial In Tourette Syndrome
Image sourced from Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
20 Stocks Moving in Friday's Pre-Market Session
Gainers Adicet Bio, Inc. (NASDAQ: ACET) rose 16% to $11.90 in pre-market trading after reporting positive clinical update from ADI-001 Phase 1 Trial in relapsed/refractory Non-Hodgkin’s Lymphoma. 
Via Benzinga
88 Biggest Movers From Yesterday
Gainers Creatd, Inc. (NASDAQ: CRTD) shares jumped 58.5% to close at $1.28 on Thursday. Creatd’s board approved a rights offering of up to $40 million for 20 million shares at $2 per unit. 
Via Benzinga
Mid-Afternoon Market Update: Dow Surges 575 Points; Apyx Medical Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining 575 points on Thursday. 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.